ECSP993262A - NEW CONTRACEPTIVE REGIME - Google Patents
NEW CONTRACEPTIVE REGIMEInfo
- Publication number
- ECSP993262A ECSP993262A ECSP993262A ECSP993262A EC SP993262 A ECSP993262 A EC SP993262A EC SP993262 A ECSP993262 A EC SP993262A EC SP993262 A ECSP993262 A EC SP993262A
- Authority
- EC
- Ecuador
- Prior art keywords
- days
- estradiol
- twelve
- regimen
- contraceptive
- Prior art date
Links
- 239000003433 contraceptive agent Substances 0.000 title abstract 3
- 230000002254 contraceptive effect Effects 0.000 title abstract 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 2
- 229960005309 estradiol Drugs 0.000 abstract 2
- 229930182833 estradiol Natural products 0.000 abstract 2
- YJSTYQGZKJHXLN-OLGWUGKESA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-11-methylidene-2,6,7,8,9,10,12,14-octahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](C)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YJSTYQGZKJHXLN-OLGWUGKESA-N 0.000 abstract 1
- 230000002051 biphasic effect Effects 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La invención está dirigida a unidades de dosificación farmacéuticas y también a un kit anticonceptivo. Se describe un régimen anticonceptivo bifásico sin un intervalo libre de hormonas. El régimen tiene 28 dias e involucra la administración diaria secuencial de únicamente estradiol durante los primeros doce a dieciséis días, y un progestágeno, a saber (17a) -17-hidroxi-11-metyilen-19-norpregna-4,15-dieno-20-in-3-ona (ORG 30659) junto con estradiol durante los doce a dieciséis dias siguientes, depués de lo cual la primera fase del ciclo siguiente comienza sin una pausa ni placebo. El orden de las fases también puede ser invertido.The invention is directed to pharmaceutical dosage units and also to a contraceptive kit. A biphasic contraceptive regimen without a hormone free interval is described. The regimen is 28 days and involves sequential daily administration of estradiol only for the first twelve to sixteen days, and a progestogen, namely (17a) -17-hydroxy-11-metyylene-19-norpregna-4,15-diene- 20-in-3-one (ORG 30659) along with estradiol for the next twelve to sixteen days, after which the first phase of the next cycle begins without a pause or placebo. The order of the phases can also be reversed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993262 ECSP993262A (en) | 1999-12-10 | 1999-12-10 | NEW CONTRACEPTIVE REGIME |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993262 ECSP993262A (en) | 1999-12-10 | 1999-12-10 | NEW CONTRACEPTIVE REGIME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP993262A true ECSP993262A (en) | 2000-02-24 |
Family
ID=42044251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP993262 ECSP993262A (en) | 1999-12-10 | 1999-12-10 | NEW CONTRACEPTIVE REGIME |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP993262A (en) |
-
1999
- 1999-12-10 EC ECSP993262 patent/ECSP993262A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG111090A (en) | CONTRACTUAL PROCESS AND FORMS OF APPLICATION FOR THE SAME | |
| PA8618301A1 (en) | EXTENDED USE OF COMBINATION THAT INCLUDES STRATENS AND PROGESTINES | |
| ES2087964T3 (en) | LOW ESTROGEN ORAL CONTRACEPTIVES. | |
| EA200201000A1 (en) | HORMONE-DESTINY THERAPY | |
| DK1126828T3 (en) | Oral administration of adenosine analogues | |
| NO986104D0 (en) | Progesterone-anti-progesterone regimens | |
| ES2190472T3 (en) | TRANSDERMIC PATCH FOR THE ADMINISTRATION OF 17-DEACETIL NORGESTIMATO, ONLY OR IN COMBINATION WITH A STROGEN. | |
| AR028809A1 (en) | AN ANTI-CONCEPTIVE METHOD AND A THREE-PHASE ORAL ANTI-CONCEPTIVE UNIT | |
| ES2096103T3 (en) | PREPARATION OF INCREASED RESISTANCE TABLETS. | |
| PE20060485A1 (en) | CONTRACEPTIVE REGIMES WITH PROGESTERONE RECEPTOR ANTAGONISTS AND KITS | |
| ES2053571T3 (en) | USE OF FLUTICASONE PROPIONATE IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INTESTINAL DISEASES. | |
| ATE292453T1 (en) | ANTIVIRAL DRUG | |
| HUP9901360A2 (en) | The use of a cimicifuga racemosa extract | |
| AR051931A1 (en) | HORMONAL TREATMENT METHODS THAT USE EXTENDED CYCLES REGIMES WITH ASCENDING DOSE | |
| EA200100226A1 (en) | TOPICAL, CONTAINING NIMESULIDE PHARMACEUTICAL COMPOSITIONS | |
| YU36401A (en) | Pharmaceutical composition for modified insulin sensitiser | |
| ECSP993262A (en) | NEW CONTRACEPTIVE REGIME | |
| CO5690602A2 (en) | EXTENDED THREE PHASE ANTICONCEPTIVE REGIMES | |
| AR039547A1 (en) | HORMONAL REPLACEMENT THERAPY | |
| ECSP941088A (en) | COMPOSITIONS | |
| BR9707772A (en) | Pharmaceutical compositions comprising natural human alpha-interferon | |
| ECSP034606A (en) | USE OF ANTIPROGESTINES FOR THE INDUCTION OF APOPTOSIS IN A CELL | |
| DK0927031T3 (en) | Pharmaceutical composition containing nimesulide for oral administration | |
| AR002946A1 (en) | A SET FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOPOROSIS IN MAMMALS ACCORDING TO A CYCLIC DIET. | |
| AR056694A1 (en) | USE OF ESTRADIOL VALERATE IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY OF THE UNITED DYSFUNCTIONAL UTERINE HEMORRAGY WITH AN ORAL ANTICONCEPTION |